NEW YORK – Point-of-care molecular diagnostics developer AmplifiDx said last week that the National Institutes of Health has increased the agency's funding for the company's development of a diagnostic testing system by $954,000, to a total of more than $4.5 million.
The funding, which was awarded through NIH's National Institute of Biomedical Imaging and Bioengineering Rapid Acceleration of Diagnostics (RADx) Tech program, will support the final stages of development of the company's AmplifiDx DX 100 Platform that will be used to perform its RespiFast nucleic acid amplification test (NAAT) for the detection and differentiation of SARS-CoV-2, flu A/B, and RSV viruses.
"This additional funding will allow us to accelerate the development of our innovative diagnostic system, helping us to bring a rapid, accurate, and affordable testing solution to market that addresses the urgent needs of healthcare providers and patients alike," AmplifiDx CEO Nancy Schoenbrunner said in a statement.
The company announced in May 2023 that it was awarded $1.4 million through the RADx program to support the development of the NAAT platform and swab-based respiratory panel. The company also received $700,000 in NIH funding to support the development of a test for Chlamydia trachomatis, Neisseria gonorrhoeae, and a high-risk human papillomavirus.
The firm said on its website that its platform is used for the simultaneous analysis of up to 10 analytes per test and it provides results within 20 minutes.